While both 177Lu-PSMA-617 and 177Lu-PSMA-I&T have established safety profiles and therapeutic effectiveness in prostate cancer, optimization of their pharmacokinetic characteristics remains an important area for further development [146,147]. This evidence concerns the gene FOLH1 and Familial prostate cancer.